Zinc acetate - Teva Pharmaceuticals
Alternative Names: ET-700; Galzin; Wilzin; Zinc acetate dihydrate - Teva PharmaceuticalsLatest Information Update: 26 May 2025
At a glance
- Originator Lemmon
- Developer Eton Pharmaceuticals; Orphan Europe; Teva Pharmaceuticals USA
- Class Acetates; Antiacnes; Antidiarrhoeals; Heavy metals
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatolenticular degeneration
Most Recent Events
- 04 Apr 2025 As of December 2024, Eton Pharmaceuticals is scheduling a meeting with the US FDA in 2025 to discuss the clinical development plan
- 03 Jan 2025 Eton Pharmaceuticals acquires Zinc acetate from Teva Pharmaceuticals
- 31 Dec 2024 Preclinical trials in Hepatolenticular degeneration in USA (PO, Controlled release), prior to December 2024